Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.42 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651366 | 0.86 | ESR2 (0.46) | PDK2CYP11B1CYP11B2BCAT1CUL4A | |
| SCHEMBL9069188 | 0.85 | ESR2 (0.43) | PDK2CYP11B1CYP11B2BCAT1GABRG2 | |
| SCHEMBL24084229 | 0.83 | PDK2 (0.43) | PDK2CYP11B1CYP11B2BCAT1CUL4A | |
| SCHEMBL2650416 | 0.81 | ESR2 (0.48) | PDK2CYP11B1CYP11B2BCAT1CUL4A | |
| SCHEMBL24084232 | 0.80 | BCAT1 (0.41) | PDK2CYP11B1CYP11B2BCAT1GABRG2 | |
| SCHEMBL2651882 | 0.80 | BCAT1 (0.41) | PDK2CYP11B1CYP11B2BCAT1CUL4A | |
| SCHEMBL20792044 | 0.80 | GABRG2 (0.47) | PDK2CYP11B1CYP11B2BCAT1GABRG2 | |
| SCHEMBL2660110 | 0.79 | CYP11B1 (0.43) | CYP11B1CYP11B2BCAT1CUL4AGABRG2 | |
| SCHEMBL9069185 | 0.79 | ESR2 (0.47) | PDK2CYP11B1CYP11B2BCAT1CUL4A | |
| SCHEMBL24085014 | 0.79 | ESR2 (0.52) | PDK2CYP11B1CYP11B2BCAT1CUL4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110082147-A1 | SUBSTITUTED IMIDAZOTRIAZINES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082147-A1 | SUBSTITUTED IMIDAZOTRIAZINES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082147-A1 | SUBSTITUTED IMIDAZOTRIAZINES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011011712-A1 | SUBSTITUTED IMIDAZOTRIAZINES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082147-A1 | SUBSTITUTED IMIDAZOTRIAZINES | GABRA5, GABRA3, GABRA2 | PDK2 2297/4885CYP11B1 916/4885CYP11B2 516/4885 |
| US-20110172280-A1 | Substituted Benzimidazoles | GABRA5, GABRB1, GABRA4 | PDK2 976/4885CYP11B1 44/4885CYP11B2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.